title: [Arterial infusion therapy with implantable port for inoperable hepatobiliary tumors].
abstract: OBJECTIVE
  To assess the clinical utility of arterial infusion therapy with implantable port for inoperable malignant hepatobiliary tumors.
  
  
  METHODS
  Twenty-seven patients with advanced hepatobiliary tumors (M:F = 14:13, mean age 63.6, 11 cases with metastases from colon cancer, 4 cases from gastric cancer, 5 cases with gallbladder cancer, 3 cases with cholangiocarcinoma, 2 cases with cholangiocellularcarcinoma, 1 case with hepatocellular carcinoma and 1 with pancreatic cancer) were treated with arterial infusion ports which were placed via left subclavian artery or femoral artery. The regimens used were FEM for 5 cases, EEP for 2 cases and FP for 20 cases.
  
  
  RESULTS
  Overall mean survival date was 241.8 days. The numbers of cases with CR, PR, NC and PD were 1, 6, 10 and 10, respectively, and the effective rate was 25.9%. Mean survivals of cases with cholangiocellularcarcinoma, metastases from gastric cancer and colon cancer were 715 days, 324.3 days and 245.9 days, respectively. Severe gastrointestinal side effects (> grade 3) were not observed. Serious bone marrow suppressions were frequently observed with FEM and EEP, but were rare with FP (10%).
  
  
  CONCLUSIONS
  Arterial infusion therapy with implantable port is clinically useful for advanced cholangiocancer and metastases from the gastrointestinal system. This system contributes to the quality of life of patients, since the infusion procedure is simple and can be archived in the outpatient clinics.
authors.affiliation: Dept. of Internal Medicine, Yujin Yamazaki Hospital.
authors.forename: S
authors.initials: S
authors.lastname: Higashi
authors.forename: C
authors.initials: C
authors.lastname: Kato
authors.forename: H
authors.initials: H
authors.lastname: Sakumoto
authors.forename: K
authors.initials: K
authors.lastname: Sumiyoshi
authors.forename: T
authors.initials: T
authors.lastname: Takahahsi
authors.forename: K
authors.initials: K
authors.lastname: Matsumoto
authors.forename: T
authors.initials: T
authors.lastname: Kane
authors.forename: M
authors.initials: M
authors.lastname: Sakoda
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: Y
authors.initials: Y
authors.lastname: Hosono
authors.forename: M
authors.initials: M
authors.lastname: Asano
authors.forename: A
authors.initials: A
authors.lastname: Yamamoto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001661:Biliary Tract Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003110:Colonic Neoplasms / Q000473:pathology; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D011379:Prognosis; D013274:Stomach Neoplasms / Q000473:pathology
chemical_list: D015251:Epirubicin; D016685:Mitomycin; D005047:Etoposide; D002945:Cisplatin; D005472:Fluorouracil